Neuronetics, Inc. (STIM)

Neuronetics' stock has experienced volatility and significant events in the past six months. From October 2024 to October 2025, the share price increased by 207.69%. In Q1 2025, Neuronetics reported a net loss of $0.21 per share, causing the stock to plummet by 21.79% in pre-market trading. The company announced inducement grants to new employees tied to achieving cash flow breakeven for specific fiscal quarters, raising investor concerns. New York State Medicaid expanded coverage for TMS therapy, including NeuroStar Advanced Therapy, to treat MDD, which is expected to provide TMS access to over 5 million New York Medicaid beneficiaries. Neuronetics announced its Q3 2025 earnings call. As of October 23, 2025, the stock was trading at $2.93, with analysts suggesting a potential upside.

Neuronetics' products and services exhibit some demand seasonality. While treatment volumes generally increased post-pandemic, there are underlying seasonal trends, but the specific nature or patterns of this seasonality are not elaborated.

Neuronetics, Inc. (STIM) is a commercial-stage neurotechnology and medical device company focused on non-invasive treatments for psychiatric disorders. Its primary product is the NeuroStar TMS Therapy System, which uses magnetic fields to stimulate brain areas for mood regulation. The NeuroStar system is FDA-cleared for treating major depressive disorder (MDD) in adults and Obsessive-Compulsive Disorder (OCD). In March 2024, it received FDA clearance as a first-line adjunct for MDD in adolescents aged 15-21. Neuronetics generates revenue through system sales, per-treatment revenue, and leasing options. The company also operates Greenbrook TMS Inc. treatment centers across the United States.

Neuronetics has a global presence and focuses on expanding its market presence both domestically and internationally. The company has established a significant market presence by partnering with healthcare institutions and private practices across the United States. While it aims for international expansion, particularly focusing on Japan, its primary sales are concentrated in the United States, with some international sales.

Neuronetics has cultivated a strong brand reputation, primarily driven by its pioneering TMS technology, established clinical data, and brand recognition. The company is recognized for its commitment to improving patient outcomes and quality of life for individuals suffering from neurohealth disorders. The NeuroStar TMS Therapy System has received FDA clearances for MDD in adults and OCD, and most recently, for adolescent MDD, reinforcing its credibility and expanding its therapeutic applications. NeuroStar is backed by the world's largest depression outcomes registry and the largest clinical data set in major depression of any TMS system, demonstrating its efficacy with up to an 83% response rate and 62% remission rate for MDD patients. Neuronetics emphasizes a patient-centric approach in designing, developing, and marketing its products.

Neuronetics, Inc. has 158 institutional owners and shareholders holding a total of 19,992,634 shares. The ownership structure includes institutional, retail, and individual investors. Institutional Investors own approximately 5.60% to 11.93% of the company's stock, Insiders own 12.96%, and Public Companies and Individual Investors own 6.34% to 75.10%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Balyasny Asset Management Llc, Ikarian Capital, LLC, Masters Capital Management Llc, Manatuck Hill Partners, LLC, Geode Capital Management, Llc, Millennium Management Llc, Morgan Stanley and Wexford Capital Lp.